InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,219.74
(
0.11%
)
US TECH 100
17,706.40
(
0.37%
)
Dow Jones
39,517.95
(
0.33%
)
Brent Oil
83.72
(
-0.28%
)
Bitcoin
62,104.96
(
-1.50%
)
Post# of 554
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

powerbattles

Send PM Follow Ignore
Followers 2426
Posts 90823
Boards Moderated 7
Alias Born 09/12/2003

powerbattles

Re: ash111 post# 514

Saturday, 06/01/2013 3:53:30 AM

Saturday, June 01, 2013 3:53:30 AM

Post# of 554
It's really don't matter for NGX-1998 Phase 3 development. They going to sell all the asset and shares holders getting nothing eom

As of April 15, 2013, NeurogesX, Inc. (the “NeurogesX”) and Acorda Therapeutics, Inc. (“Acorda”) entered into an Asset Purchase Agreement (the “APA”). Pursuant to the terms of the APA, Acorda will acquire at the closing certain assets of NeurogesX (including NeurogesX’ assets relating to its product Qutenza and its product candidate NGX-1998),

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up